Fortrea (FTRE) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Fortrea (FTRE) do?
Fortrea Holdings Inc (FTRE) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Provides clinical trial management, patient recruitment, and regulatory consulting services for pharmaceutical companies. Manages phase one through four clinical drug trials globally for pharmaceutical and biotechnology sponsors. It is worth $1.94B on the market and sold $2.66B over the last year.
- Market cap
- $1.94B
- P/E ratio
- None (reported a loss)
- Annual sales
- $2.66B
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 17, 2026
FTRE’s flags, in plain English
Each flag is a number from Fortrea’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.
Growth vs Price
The price looks reasonable for how fast it is growing. The price looks reasonable for how fast its profits are growing.
Cheap on Cash Flow
Priced at 11.5 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.
Debt Is Driving
Heavy debt, 210% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about FTRE
How big is Fortrea?
Fortrea’s market cap is $1.94B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.66B: what customers paid the company over the last year, before any costs.
What is FTRE’s P/E ratio?
FTRE has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with FTRE?
A large share of total revenue depends on clinical trial spending by biotechnology companies that face tight financing conditions. That is one risk on Fortrea’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Fortrea’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. FTRE’s filings on SEC.gov. The Margin Monkey is research, not advice.
